Home » TISSUEGENE BEGINS TRIAL OF CARTILAGE REPAIR DRUG
TISSUEGENE BEGINS TRIAL OF CARTILAGE REPAIR DRUG
TissueGene has announced FDA acceptance of an investigational new drug application and the initiation of its Phase I clinical trial evaluating a single dose of TG-C for the treatment of degenerative joint diseases. This clinical trial is designed to assess the safety of TG-C in patients who have opted for total knee arthroplasty.
TissueGene has developed TG-C to regenerate cartilage in patients suffering from degenerative arthritis, more specifically for osteoarthritis of the knee. As an alternative to other methods of cartilage repair, TG-C will involve minimally invasive injections versus a surgical approach. Other techniques currently involve multiple and often invasive surgical procedures and have mixed results.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
07May
-
14May
-
30May